发现与G蛋白结合的受体向生物制剂的技术
McKenna L Downey1, Pamela Peralta-Yahya2
1School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Current opinion in biotechnology
|May 10, 2024
概括
针对G蛋白结合受体 (GPCRs) 的生物药物正在成为强大的治疗方法. 新技术加速了针对各种疾病的GPCR向生物制剂的发现和工程.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 分子生物学分子生物学
背景情况:
- G蛋白结合受体 (GPCR) 是代谢,神经和心血管疾病的关键药物标.
- 虽然小分子主导着GPCR疗法,但生物制剂如和抗体在临床试验和批准的药物中越来越突出.
研究的目的:
- 审查针对GPCRs的工程生物学的尖端技术.
- 突出适合GPCR生物开发的新兴技术.
- 提供适用于发现人类GPCRs生物制剂的相邻技术的概述.
主要方法:
- 对GPCR生物工程的最先进技术的审查.
- 讨论用于显示测试的计算设计库.
- 综述合成生物学在高通量功能GPCR测定方面的进展.
主要成果:
- 廉价的DNA合成有助于快速生成GPCR绑定器库.
- 合成生物学使GPCR调节生物学的高通量选成为可能.
- 邻近的技术为GPCR生物发现提供了新的途径.
结论:
- 技术进步正在迅速提高GPCR向生物制剂的发现和工程.
- 计算设计,合成生物学和显示分析的整合加速了治疗的发展.
- 未来的研究将利用这些技术来扩大针对GPCR介导疾病的生物药物库.
相关概念视频
Transducer Mechanism: G Protein–Coupled Receptors
1.9K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.9K
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
G-protein Coupled Receptors
118.4K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
118.4K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K


